Views & Analysis ESMO review: advances in immunotherapy, EMA dialogue and pa... QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
ESMO2016 Cancer Market Commentary: Keytruda’s triumph not the last wo... Despite Keytruda's overwhelming victory, it's not over yet in NSCLC
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
